methazolamide has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X | 1 |
| Li, Y | 1 |
| Yuan, X | 1 |
| Yuan, W | 1 |
| Li, C | 1 |
| Zeng, Y | 1 |
| Lian, Y | 1 |
| Qiu, X | 1 |
| Qin, Y | 1 |
| Zhang, G | 1 |
| Liu, X | 1 |
| Luo, C | 1 |
| Luo, JD | 1 |
| Hou, N | 1 |
1 other study available for methazolamide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Methazolamide Attenuates the Development of Diabetic Cardiomyopathy by Promoting β-Catenin Degradation in Type 1 Diabetic Mice.
Topics: Animals; Axin Protein; beta Catenin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dia | 2022 |